Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
In: Addiction Science & Clinical Practice, Jg. 17 (2022-01-29), Heft 1, S. 1-9
Online
academicJournal
Zugriff:
Background: Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receiving XRB as a jail-to-community treatment. Methods and findings: In-depth qualitative interviews were conducted among adult participants with opioid use disorder (OUD; n = 16) who were recently released from NYC jails and maintained on XRB after switching from daily sublingual buprenorphine (SLB). Interviews elaborated on the acceptability and barriers and facilitators of XRB treatment pre- and post-release. Interviews were audio recorded, transcribed, and analyzed for content related to factors influencing XRB treatment uptake and community reentry. Important themes were grouped into systems, medication, and patient-level factors. Key systems-level factors influencing initiation of XRB in jail included an alternative to perceived stigmatization and privacy concerns associated with daily in-jail SLB administration and less concerns with buprenorphine diversion. In-jail peer networks positively influenced participant adoption of XRB. XRB satisfaction was attributed to reduced in-jail clinic and medication administration visits, perceived efficacy and blockade effects upon the use of heroin/fentanyl following release, and averting the risk of criminal activities to fund opioid use. Barriers to retention included post-injection withdrawal symptoms and cravings attributed to perceived suboptimal medication dosing, injection site pain, and lack of in-jail provider information about the medication. Conclusion: Participants were generally favorable to XRB initiation in jail and retention post-release. Further studies are needed to address factors influencing access to XRB in criminal justice settings, including stigma, ensuring patient privacy following initiation on XRB, and patient-, provider-, and correctional staff education pertaining to XRB. Trial Registration ClinicalTrials.gov Identified: NCT03604159. [ABSTRACT FROM AUTHOR]
Copyright of Addiction Science & Clinical Practice is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study.
|
---|---|
Autor/in / Beteiligte Person: | Cheng, Anna ; Badolato, Ryan ; Segoshi, Andrew ; McDonald, Ryan ; Malone, Mia ; Vasudevan, Kumar ; Badiei, Beita ; Sugarman, Allison ; Macdonald, Ross ; Mangat, Jasdeep ; Giftos, Jonathan ; Lee, Joshua D. ; Tofighi, Babak |
Link: | |
Zeitschrift: | Addiction Science & Clinical Practice, Jg. 17 (2022-01-29), Heft 1, S. 1-9 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 1940-0632 (print) |
DOI: | 10.1186/s13722-022-00288-4 |
Schlagwort: |
|
Sonstiges: |
|